At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 690 enrolled
Drug / intervention
Treprostinil Diolamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
In Brief
A Phase 3 clinical trial evaluating Treprostinil Diolamine and Placebo for Pulmonary Arterial Hypertension. Completed, enrolled 690 participants across 155 sites in 23 countries.
Detailed Summary
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesArgentina, Australia, Austria, Brazil, Canada, Chile, China, Denmark, France, Germany, Greece, India, Israel, Italy, Mexico, Netherlands, Poland, Singapore, South Korea, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartJun 2012
Primary CompletionJun 2018
TodayJul 2026
First PostedMar 22, 2012
Enrollment StartJun 26, 2012
Primary CompletionJun 24, 2018
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 14.3 years ago
Interventions
Treprostinil Diolaminedrug
Active
Placebodrug
Placebo